Zhaozhen Wu

28 Fuxing Road
Haidian, 100853, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Alectinib versus crizotinib as the first-line treatment in patients with advanced ALK-positive non-small cell lung cancer: a Chinese real-world cohort study.

Alectinib versus crizotinib as the first-line treatment in patients with advanced ALK-positive non-small cell lung cancer: a Chinese real-world cohort study.

Journal: Translational lung cancer research

Published: September 30, 2025

Prognostic Value of C-Reactive Protein-to-Lymphocyte Ratio in Combined Immunotherapy and Chemotherapy for Small Cell Lung Cancer.

Prognostic Value of C-Reactive Protein-to-Lymphocyte Ratio in Combined Immunotherapy and Chemotherapy for Small Cell Lung Cancer.

Journal: Journal of inflammation research

Published: March 12, 2025

The efficacy and safety of chemotherapy with or without anti-PD-1 for the first-line treatment of advanced urothelial carcinoma.

The efficacy and safety of chemotherapy with or without anti-PD-1 for the first-line treatment of advanced urothelial carcinoma.

Journal: Cancer medicine

Published: March 14, 2023

The gut microbiota modulates responses to anti-PD-1 and chemotherapy combination therapy and related adverse events in patients with advanced solid tumors.

The gut microbiota modulates responses to anti-PD-1 and chemotherapy combination therapy and related adverse events in patients with advanced solid tumors.

Journal: Frontiers in oncology

Published: March 01, 2022

Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors.

Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors.

Journal: Journal of hepatocellular carcinoma

Published: August 18, 2020

Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis.

Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis.

Journal: Frontiers in oncology

Published: July 31, 2020

Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma.

Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma.

Journal: Journal of cancer research and clinical oncology

Published: May 20, 2020

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors.

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors.

Journal: Clinical Medicine Insights. Oncology

Published: May 08, 2020

Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting.

Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting.

Journal: Cancer immunology, immunotherapy : CII

Published: March 30, 2020

Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC.

Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC.

Journal: Scientific reports

Published: March 04, 2020

Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer.

Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer.

Journal: Targeted oncology

Published: February 14, 2020

Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer.

Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer.

Journal: Therapeutic advances in medical oncology

Published: January 23, 2020

Showing 1-12 of 18

Last Updated: 09/26/2026